Press Release

02 September 2021

Veritas In Silico and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based RNA-targeting small molecule Drug Discovery

CHENGDU, China, Sep 2nd, 2021-- Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”) and Veritas In Silico Inc. (“Veritas In Silico”), a Tokyo-based private company, today announced that they have entered into a research collaboration agreement to discover small molecule compounds against RNA targets. Veritas In Silico will apply its drug discovery platform, ibVIS, to identify certain RNA targets that are of interest to Veritas In Silico.
31 August 2021

Infographic | HitGen FY2021 Mid-term Report

HitGen FY2021 Mid-term Report
10 June 2021

Vernalis, a fully owned subsidiary of HitGen Inc., and Servier achieve two milestones in their oncology drug discovery collaboration

Chengdu, China, 10 June 2021 – Vernalis, a fully owned subsidiary of HitGen Inc., and Servier are pleased to announce the achievement of one research and one pre-clinical milestone in their oncology drug discovery collaboration, triggering undisclosed milestone payments to Vernalis.
27 May 2021

Available now! Whitepaper: Advancing Drug Discovery through DNA Encoded Library Technology!

CHENGDU, China, May 27th, 2021 HitGen and Fierce Biotech jointly release the Whitepaper: Advancing Drug Discovery through DNA-Encoded Library (DEL) Technology today. This whitepaper will provide the drug discovery community with an in depth dive of DEL technology and stimulate innovation in the field by describing HitGen’s experiences and knowledges on DEL design, synthesis, screening and expanded applications.
24 May 2021

Dorian and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery

CHENGDU, China, May 24th, 2021-- Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”) today announced that it has entered into a research collaboration agreement with Dorian Therapeutics, Inc.
13 May 2021

Coming Soon! Whitepaper: Advancing Drug Discovery through DNA-Encoded Library Technology！

Since its concept was conceived in 1992, DNA-encoded chemical libraries (DELs) have evolved into a valuable technology for hit identification in drug discovery.
06 April 2021

HitGen and BioAge Announce Research Progress in DNA-Encoded Library Based Drug Discovery Research Collaboration

On 6th April 2021, CHENGDU, China-- Shanghai Stock Exchange listed biotech company HitGen Inc. (“HitGen”) announced important research progress in a collaboration with BioAge Labs, Inc. (“BioAge”), a private biotechnology company developing targeted small molecules for the treatment of diseases of aging. The companies have conducted collaborative research to identify and develop novel small-molecule compounds against a high-value and challenging biological target that is a critical component of the innate immune system. Dysregulation of this target is closely linked to the underlying cause of severe diseases in elderly humans, such as Alzheimer's and cardiovascular disease.
10 March 2021

Lipigon expands collaboration with HitGen by selecting second target

Chengdu, China March 10th, 2021 Lipigon Pharmaceuticals AB (”Lipigon”), developer of therapeutics for lipid-related diseases, today announced that the company has expanded its agreement with the Shanghai STAR listed company HitGen Inc. (”HitGen”) to include a second novel target. With joint efforts, the aim is to develop a treatment for cardiometabolic disease.
01 March 2021

HitGen and UPPTHERA Enter Into Drug Discovery Research Collaboration

CHENGDU, China, March 1st, 2021 -- HitGen (688222.SH) today announced that it has entered into a drug discovery research collaboration with UPPTHERA Inc. to identify small molecule Hits against previous known-to-be undruggable targets and novel E3 ligase. HitGen will apply its platform technology, based on the design, synthesis and screening of DNA-encoded libraries (DEL) to discover compounds that bind to certain targets. The identified compounds will be exclusively licensed to UPPTHERA for further development. Under the terms of the agreement, HitGen will receive an undisclosed upfront payment, success fee, license/milestone fee from UPPTHERA.
21 December 2020

HitGen announces License Agreement with Merck & Co., Inc., Kenilworth, NJ USA to access compounds for potential development of a novel class of drugs

Chengdu, CHINA, December 21th 2020 HitGen Inc. is pleased to announce that HitGen and Merck & Co., Inc., Kenilworth, NJ USA, known as MSD outside the United States and Canada, expand their collaboration with a license to develop a novel class of drugs for an early target of high interest.

News

Press Release

Thanks for reading!